Apricus Biosciences (NASDAQ: APRI ) is hoping to widen its capital base significantly. The company is floating a mix of common stock and warrants that it hopes will raise net proceeds of nearly $16 million. Six million shares will be sold in an underwritten public offering at $2.85 apiece, and 3 million warrants will be issued separately at an exercise price of $3.40 per share.
Additionally, the company's underwriters have been granted a 30-day purchase option for up to an additional 900,000 shares and 450,000 warrants to cover over-allotments, if any.
Apricus Bio said it plans to use the proceeds of the issue for capital expenditures, research and development activities, clinical trial costs, and "general corporate purposes."
Lazard's Lazard Capital Markets is the sole book-running manager of the issue.